Table 1.
Cats participating in the study, including signalment, number of additional cats in the household, method of diagnosis of feline infectious peritonitis (FIP), FIP-associated signs, Xraphconn® treatment dose, other diseases at the start of and developing during treatment, adverse effects, and additional symptomatic therapy.
| Cat | Age (Months) | Sex | Breed | Additional Cats in the Household (Number) | Diagnosis of FIP 1 | FIP-Associated Cardinal Signs | Dosage (mg/kg q24h) |
Adverse Effects and Duration (on Days of Treatment) | Other Unrelated Diseases before Treatment | Other Unrelated Diseases Developing during Treatment | Additional Symptomatic Therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| cat 1 | 6.0 | male neutered |
ESH | yes (1) | immunohisto-chemistry (eye) |
ocular signs | 10 mg/kg | lymphocytosis (2–end2) | fluid therapy 3, metamizole 4 | ||
| cat 2 | 6.3 | male intact |
ESH | yes (1) | immunohisto-chemistry (eye) |
neurologic signs, ocular signs | 10 mg/kg | lymphocytosis (0–end) | surgical wound infection after eye enucleation | fluid therapy, antibiotics 5, buprenorphine 6 | |
| cat 3 | 9.8 | male neutered |
ESH | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | increased liver enzyme activity (4–14) | renal mineraliza-tion | fluid therapy, antibiotics, maropitant 7, mirtazapine 8 | |
| cat 4 | 7.2 | male intact |
ESH | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (2–end), eosinophilia (14–56) |
fluid therapy, metamizole-sodium, antibiotics, maropitant, mirtazapine | ||
| cat 5 | 6.4 | female intact |
ESH | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (0–end), increased liver enzyme activity (4–83), eosinophilia (14–end) |
fluid therapy, antibiotics | ||
| cat 6 | 10.7 | male neutered |
ESH | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (83–end) | antibiotics, mirtazapine | ||
| cat 7 | 4.7 | male intact |
Siamese | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion, thoracic effusion | 5 mg/kg | lymphocytosis (0–end), increased liver enzyme activity (4–83), eosinophilia (14–end) |
chronic gingivo-stomatitis | fluid therapy, antibiotics, silymarin 9 | |
| cat 8 | 6.4 | male intact |
Maine Coon | no | RT-PCR detecting S gene mutations (effusion) | thoracic effusion | 5 mg/kg | lymphocytosis (0–14), eosinophilia (14–83) |
chronic gingivo- stomatitis |
fluid therapy, antibiotics, oxygen cage 10 | |
| cat 9 | 8.9 | male neutered |
ESH | yes (3) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (28–end), increased liver enzyme activity (4–83), eosinophilia (28–end) |
fluid therapy, antibiotics, mirtazapine, silymarin | ||
| cat 10 | 39.1 | female neutered |
ESH | yes (3) | immunohisto-chemistry (lymph node) |
abdominal effusion | 5 mg/kg | eosinophilia (0–end) | intestinal parasite infestation (Giardia spp., treated with fenbendazole) | ||
| cat 11 | 56.5 | female neutered |
ESH | yes (3) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (0–14), increased liver enzyme activity (4–97) |
fluid therapy, antibiotics | ||
| cat 12 | 11.7 | male neutered |
Birman | yes (1) | immunohisto-chemistry (lymphnode), RT-PCR detecting S gene mutations (effusion) |
thoracic effusion | 5 mg/kg | lymphocytosis (2–end), increased liver enzyme activity (28–56), eosinophilia (28–83) |
fluid therapy, antibiotics, buprenorphine | ||
| cat 13 | 28.8 | female intact |
Maine Coon | yes (9) | RT-PCR detecting S gene mutations (effusion) | thoracic effusion | 5 mg/kg | eosinophilia (28–end) | rhinitis | fluid therapy, antibiotics | |
| cat 14 | 7.5 | male intact |
ESH | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | intestinal parasite infestation (Giardia spp., treated with fenbendazole) | fluid therapy, antibiotics, maropitant, mirtazapine, buprenorphine, pregabalin 11 | ||
| cat 15 | 7.6 | male intact |
Maine Coon | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (2–56), eosinophilia (2–28) |
distorsion on right forelimb | fluid therapy, antibiotics, buprenorphine, meloxicam 12 | |
| cat 16 | 8.9 | female neutered |
BSH | yes (1) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (7–14), increased liver enzyme activity (2–14) |
chronic gingivo-stomatitis | fluid therapy, mirtazapine | |
| cat 17 | 7.7 | male intact |
Scottish Fold | yes (1) | RT-PCR detecting S gene mutations (effusion) | thoracic effusion | 5 mg/kg | lymphocytosis (2–end), eosinophilia (28–end) |
otitis externa | pyothorax | fluid therapy, antibiotics |
| cat 18 | 7.6 | female intact |
ESH | yes (2) | RT-PCR detecting S gene mutations (effusion) | abdominal effusion | 5 mg/kg | lymphocytosis (0–end), eosinophilia (2–end) |
fluid therapy, antibiotics |
mg, milligram; kg, kilogram; q24h, every 24 h; ESH, European shorthair; RT-PCR, reverse transcription polymerase chain reaction; S, spike; BSH, British shorthair; spp., species. 1 diagnosis of FIP: FIP confirmed: positive IHC plus consistent histopathology; FIP very likely: positive RT-PCR and analysis for FCoV spike mutation. 2 end: until the end of the observation period. 3 fluid therapy with Ringer’s lactate with potassium supplementation at 20 mval/L for dehydration at an individual dosage calculated by rehydration and maintenance needs. 4 metamizole 30 mg/kg intravenously (IV) for treatment of fever (body temperature > 40.5 °C) as a single injection. 5 antibiotics (i.e., amoxicillin/clavulanic acid 20 mg/kg q8h IV or per os (PO); trimethoprim sulfadiazin 20 mg/kg q12h IV or PO; marbofloxacin 2 mg/kg q24h IV; pradofloxacin 6 mg/kg q24h PO; ampicillin 12.5 mg/kg q8h IV for treatment of secondary suspected or proven bacterial infection (neutrophilia with left shift or continuously high body temperature). 6 buprenorphine 0.01 mg/kg q8h IV for treatment of pain. 7 maropitant 1 mg/kg q24h IV for treatment of gastrointestinal signs, such as vomiting and anorexia. 8 mirtazapine ointment q24h for appetite stimulation. 9 silymarin 20 mg/kg q12h PO for 10 days and then 20 mg/kg q24h PO for treatment of increased liver enzymes. 10 oxygen cage for support in cases of dyspnea in cats with massive thoracic effusion. 11 pregabalin 2 mg/kg q12h PO when buprenorphine was not sufficient to control pain. 12 meloxicam 0.1 mg/kg q24h PO for 1 day and then 0.05 mg/kg q24h PO for treatment of orthopedic pain.